Genmab Affirms FY2026 Sales Guidance of $4.325B-$4.525B vs $4.472B Est
Genmab (NASDAQ:GMAB) affirms FY2026 sales outlook from $4.325 billion-$4.525 billion to $4.325 billion-$4.525 billion vs $4.472 billion estimate.
Share
Why It Matters
Genmab stuck with its sales forecast for next year. The company's numbers land right around what experts expected.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.